Achieving significant changes in medical practice
Since 1991, we have undertaken clinical trial research to improve treatments for patients with GI cancer. We pride ourselves on our independent, patient centred research and following are some of the results of our collaborative multi-disciplinary trials.
We have extended life expectancy for patients with GI cancer by testing:
- Oral chemotherapy as an alternative to intravenous therapies
- New drug treatments
- Targeted therapies and personalised therapy
- Preoperative chemo radiation
- Novel combinations of treatments
We have improved quality-of-life for patients by:
- Reducing side affects by a different combination of chemotherapies
- Identifying patients who do not benefit from certain therapies.
- Demonstrating that a shorter duration of treatment is equally efficacious but less toxic in the adjuvant treatment of colorectal cancer
We have tested new targeted therapies:
- Demonstrating that a drug that acts on tumour growth is safe and active in oesophageal cancer
- Showing that a monoclonal antibody treatment is likely to benefit selected patients with bile duct cancer
We are now starting to test preventative therapies in GI cancer.